Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quest Pharmatech Inc V.QPT

Alternate Symbol(s):  QPTFF

Healthcare Biotechnology
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy... see more

Bullboard (TSXV:QPT)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next
Post by G1945Von Jun 02, 2024 8:40am

Canada NewsWire 2 days ago-updates on SEDAR

Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director Quest is also pleased to announce the ...more  
237
Comment by G1945Von Mar 19, 2024 6:18am

RE:RE:RE:RE:RE:Interesting

In addition to the above, I highly doubt Shenzhen Hepalink a 15% owner of QPT will let Canaribio run away with Oregovomab unchallenged if that is where their intentions lie. Hepalink, our poison pill, ...more  
182
Discussion
Comment by G1945Von Mar 18, 2024 6:26pm

RE:RE:RE:RE:Interesting

Let the Clinical Trial play out. Canaribio is on the hook no matter what. Let's hope Phase 111 succeeds. If it doesn't, Oregovomab would be worthless. Madiyalakan the CEO of both QPT & ...more  
139
Discussion
Comment by TrickyGameon Mar 18, 2024 5:53pm

RE:RE:RE:Interesting

With $300 million deal that was done wrong denying QPT the cash for their 45% interest in oregovomab and that same 45% interest in oregovomab's potential sales I'm sure QPT will be able to ...more  
125
Discussion
Comment by ARIMA11on Mar 18, 2024 5:26pm

RE:RE:Interesting

Not sure if tQPT have the funds for a lenghty legal battle with Canaribio in court. QPT have little revenues. Hoping that Canaribio will eventually provide some money (cash) which would help. Frankly ...more  
94
Discussion
Comment by TrickyGameon Mar 18, 2024 1:26pm

RE:Interesting

I believe QPT has said they are willing to go to court to protect thier 45% interest in oregovomab. At best they end up getting Carariabio bonds and shares as payment for theier interest in oregovomab ...more  
110
Discussion
Comment by ARIMA11on Mar 17, 2024 10:28pm

RE:Interesting

https://www.hepalink.com/en/MedicineBusiness/index.aspx https://www.hepalink.com/OncoVent/en/oreg.html Worth keeping an eye on this...
86
Discussion
Post by ARIMA11on Mar 17, 2024 10:11pm

Interesting

https://canariabio.com/eng/rnd/pipeline.php Still alot of phase II ongoing. Also this in the last meaningful release. https://ceo.ca/@newswire/oregovomab-phase-iii-clinical-study-fails-futility The ...more  
190
Discussion
Post by ARIMA11on Jan 24, 2024 8:13pm

Interesting

https://www.annalsofoncology.org/article/S0923-7534(19)32244-6/fulltext Conclusions Careful consideration should be given to the decision to terminate a study for futility, as futility ...more  
277
Comment by ARIMA11on Jan 24, 2024 8:07pm

RE:RE:RE:RE:RE:Why did the Study fail?

Again, 61% of the trades today involved Anonymous brokers (1)   24-Jan 0.02 95000 1 7 24-Jan 3:29:09 PM 0.02 10,000 1 7 24-Jan 3:28:54 PM 0.02 10,000 1 7 24-Jan 12:55:23 PM 0.025 29,000 ...more  
134
Discussion
Comment by ARIMA11on Jan 24, 2024 8:01pm

RE:RE:RE:RE:Why did the Study fail?

Yes. They should. However, this release is very contradictory. On one hand, it not good and on the other its hopeful. Details are very sparse. Question at this point is are: 1. What is the make up of ...more  
187
Discussion
Comment by G1945Von Jan 24, 2024 7:34pm

RE:RE:RE:Why did the Study fail?

Yes, that's my understanding. Management should put out a simple explanation. G1945V
106
Discussion
Comment by TrickyGameon Jan 24, 2024 6:12pm

RE:RE:Why did the Study fail?

So you are saying the "interim progression-free survival" part of the study will be discontinued but the "overall survival" part of the study will continue? So there is still a ...more  
140
Discussion
Comment by G1945Von Jan 24, 2024 3:39pm

RE:Why did the Study fail?

I believe that the DSMB is only advising CAB to discontinue the clinical trial for interim "progression-free survival" in the study subjects due to the futility evaluation. But recommends ...more  
136
Discussion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities